Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a, Double-Blind, Randomized Adaptive Design, Placebo-Controlled, Parallel Group Study to Evaluate the Safety, Tolerability, Efficacy, PK and Biomarkers with Oral Colon Delivery PL8177 in Adult Subjects with Active Ulcerative Colitis

NCT05466890 is registered in ClinicalTrials.gov with Palatin Technologies, Inc as lead sponsor.

NCT NCT05466890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05466890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a, Double-Blind, Randomized Adaptive Design, Placebo-Controlled, Parallel Group Study to Evaluate the Safety, Tolerability, Efficacy, PK and Biomarkers with Oral Colon Delivery PL8177 in Adult Subjects with Active Ulcerative Colitis
Lead sponsor
Palatin Technologies, Inc
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 15, 2022
Completion date
March 31, 2025
Enrollment
16 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative, ulcerative colitis, ulcerative colitis acute, ulcerative colitis flare